Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00832572 · ClinicalTrials.gov registry record · Phase 4
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
A Phase 4 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00832572: Clinical Trial Phase 4 study, sponsored by Gilead Sciences.
NCT00832572 is a Phase 4 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00832572, a Phase 4 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.
Primary Outcome
Reduction in patient-reported neuropathic pain (by 2 numeric levels as measured by the Numeric Pain Scale)
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Why NCT00832572 stopped before completion
NCT00832572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00832572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00832572 about?
NCT00832572 is a clinical study titled "Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy". This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinde...
What is the current status of trial NCT00832572?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2009-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00832572?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT00832572?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00832572's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia